The aim of this study was to develop a new model of sporadic Parkinson disease (PD) based on silencing of the SKP1A gene, a component of the ubiquitin-proteasome/E3 ligase complex, Skp1, Cullin 1, F-box protein, which was found to be highly decreased in the substantia nigra of sporadic PD patients. Initially, an embryonic mouse substantia nigra-derived cell line (SN4741 cells) was infected with short hairpin RNA lentiviruses encoding the murine transcript of the SKP1A gene or with scrambled vector. SKP1A silencing resulted in increased susceptibility to neuronal damages induced by the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium ion and serum starvation, in parallel with a decline in the expression of the dopaminergic markers, dopamine transporter and vesicular monoamine transporter-2. SKP1A-deficient cells presented a delay in completion of the cell cycle and the inability to arrest at the G 0 /G 1 phase when induced to differentiate. Instead, the cells progressed through S phase, developing rounded aggregates with characteristics of aggresomes including immunoreactivity for ␥-tubulin, ␣-synuclein, ubiquitin, tyrosine hydroxylase, Hsc-70 (70-kDa heat shock cognate protein), and proteasome subunit, and culminating in a lethal phenotype. Conversely, stably enforced expression of wild type SKP1A duplicated the survival index of naïve SN4741 cells under proteasomal inhibition injury, suggesting a new structural role of SKP1 in dopaminergic neuronal function, besides its E3 ligase activity. These results link, for the first time, SKP1 to dopamine neuronal function and survival, suggesting an essential role in sporadic PD. In summary, this new model has reproduced to a significant extent the molecular alterations described in sporadic PD at the cellular level, implicating Skp1 as a potential modifier in sporadic PD neurodegeneration.
Human post-mortem brain tissue gene expression profiling in sporadic Parkinson disease (PD) 2 has revealed significant dysregulation of genes involved in biological processes linked to protein aggregation and catabolism, mitochondrial dysfunction, oxidative stress, cell cycle, vesicle trafficking, synaptic transmission, dopamine (DA) metabolism, and cell adhesion/ cytoskeleton maintenance (1) (2) (3) (4) (5) . One of them, SKP1A (p19, S phase kinase-associated protein 1A), an essential component of protein catabolism, has been found to be significantly decreased in the substantia nigra pars compacta (SNpc) of postmortem parkinsonian brains compared with age-matched controls at the gene and protein level (1, 6) . Skp1 protein is a component of the largest class of E3 ubiquitin ligases, functioning within modular multiprotein SCF (Skp1, Cullin 1, a substraterecognizing F-box protein and Rbx1) (7, 8) . SCF complexes are modular: Skp1 can interact with several F-box proteins that are responsible for specific target recognition, thereby increasing the repertoire of different proteins targeted by this complex. The finding that Skp1 is decreased inside the melanized postmitotic neurons of the SNpc from PD brains (6) and that humans express only one functional Skp1 isoform (9) may partly account for a wide impairment in the function of an entire repertoire of proteins implicated in dopaminergic neurotransmission. Ubiquitination and proteasomal-mediated protein handling defects are thought to be common features in PD and other chronic neurodegenerative diseases such as Alzheimer disease, amyotrophic lateral sclerosis, and Huntington disease and in aging (10, 11) . This is suggested to affect several cellular processes associated with ubiquitination such as cell cycle, intracellular trafficking, signaling pathways, degradation, and aggregation of normal and damaged intracellular proteins. A significant body of evidence points to a crucial role for protein misfolding and aggregation in the formation of protein inclusion bodies or Lewy bodies (LBs) in sporadic PD. A loss of 20 S proteasome ␣-subunits and reduction in the activity of the 26/20 S proteasome system in SNpc of sporadic PD has also been reported (12, 13) . A role for the ubiquitin proteasome system in PD pathogenesis has received support from the finding that mutations in the E3 ubiquitin ligase parkin, cause early onset, autosomal recessive PD, characterized by midbrain DA neuron loss (14) . Functional loss as a consequence of mutations present at different regions of the parkin protein is suggested to exert a profound effect on its function, resulting from its aggregation into inclusion bodies and disturbance in cell localization (15, 16) . Furthermore, disease-linked point mutations in parkin, which retain their catalytic E3 ligase activity, have a propensity to mislocalize within the cell and aggregate in inclusion bodies (17) . This implies that disruption of the cytoplasmic co-localization with essential protein partners may constitute the molecular basis of the loss of parkin function. Neuronal and non-neuronal cells overexpressing parkin form large, noncytotoxic cytoplasmic inclusions under proteasomal inhibition (18) .
Besides SKP1A, our pioneer large scale transcriptomics analysis of gene expression profile of sporadic PD SNpc (1) has identified a number of differentially expressed genes participating in the neurotoxic cascade of DA neurons death, in particular those related to the handling of proteins, dopaminergic transmission, and metabolism. One such gene is HSPA8 (heat shock 70-kDa protein 8), coding for Hsc-70 (70 kDa heat-shock cognate protein), a member of the Hsp70 family whose expression was severely reduced in PD SN. Hsc-70 acts as a chaperone responsible for recognition of unfolded or aberrant proteins and delivery to a co-chaperone, E3 ligase enzyme CHIP (carboxyl terminus of Hsc70-interacting protein), which in turn, can cooperate with Hsp90 and/or Hsp70/Hsc-70 and ubiquitinate their attached misfolded substrates (19) . Recent confirmatory immunohistochemical studies in the PD SNpc (6) revealed a discrete Hsc-70-positive stain delineating the halo of the LB. This localization is not surprising because molecular chaperones as well as ubiquitin and proteasome subunits are recruited to the LB and other inclusion bodies (20, 21) . Additional reductions were observed in the DA transporter (DAT) and vesicular monoamine transporter-2 (VMAT2), both key components in the regulation of DA disposition in the synapse and cytosol. Also, the genes coding for alcohol dehydrogenase, family 5, and aldehyde dehydrogenase (aldehyde dehydrogenase family 1, subfamily A1 (ALDH1A1)), both involved in the degradation of aldehyde derivatives of DA, generated by the action of MAO-A and -B, were down-regulated. These highly reactive, neurotoxic aldehydes can accumulate in case of decreased levels of ALDH and ADH, as occurs in SNpc of PD, and can promote neuronal death (22, 23) .
Previous studies aimed at developing transgenic models of PD by knock-out or overexpressing single familial PD mutated genes have not met with the expected success because the cell types that are affected typically do not mirror those that are vulnerable in human sporadic PD (24 -26) . Thus, the various forms of familial PD, as caused by gene mutation, will not contribute to the identification of the final cascade of molecular events that result in degeneration of DA neurons in sporadic PD. In the present study we sought to investigate the impact of RNA interference-mediated silencing of SKP1A, found significantly reduced in sporadic PD SNpc (1), on the survival of differentiated mesencephalic embryonically derived SN4741 dopaminergic cell line and expression of dopaminergic phenotype markers. The ultimate goal is to develop a genetic model of sporadic PD that recapitulates, at the cellular level, the central molecular pathology occurring in DA neuron degeneration in PD.
EXPERIMENTAL PROCEDURES
Materials-Media, serum, antibiotics, and supplements were purchased from Biological Industries (Beit-Haémek, Israel). Phosphatase inhibitor, puromycin dihydrochloride, hygromycin B, hexadimethrine bromide (Poly Bren), 1-methyl-4-phenylpyridinium ion (MPP ϩ ), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), and N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) were from Sigma. MG-132 was from Calbiochem (La Jolla, CA). Mouse monoclonal ␤-actin antibody (antibody A5441, 1:20,000) was from Sigma. Donkey serum, secondary donkey anti-rabbit IgG Cy2-conjugated, and donkey anti-mouse IgG-tetra-methyl-rhodamine-conjugated antibodies (1:750) were from Jackson ImmunoResearch (Baltimore, MD). Other chemicals and reagents were of the highest analytical grade and were purchased from local commercial sources.
Cell Culture and Experimental Procedures-SN4741, a mouse embryonic substantia nigra-derived cell line carrying the temperature-sensitive mutant from the oncogene SV40Tag-tsA58, was grown at 33°C in 5% CO 2 humidified atmosphere in Dulbecco's modified Eagle's medium containing high glucose (4.5 mg/ml) supplemented with 2 mM L-glutamine, penicillin/streptomycin/nystatin (100 units/ml) and 10% heat-inactivated fetal calf serum (FCS). For differentiation studies, the cells plated in sixwell culture dishes or in 10-cm 2 plates were shifted to 39°C (nonpermissive temperature) in medium containing 0.5% FCS for 2 days. For differentiation with retinoic acid, the latter was added to the culture daily at a final concentration of 10 M in 1% FCS-containing medium, without replacing the medium. HEK293T cells were plated in 10-cm culture dishes in a growth medium containing Dulbecco's modified Eagle's medium with 4.5 mg/ml glucose, 2 mM L-glutamine, supplemented with 100 units/ml (1%) of a mixture of penicillin/streptomycin/nystatin and 10% (v/v) FCS. The cell cultures were incubated at 37°C in humid 5% CO 2 , 95% air environment.
Cell Viability and Death Assays-SN4741 cells were placed in 96-well microtiter plates at a density of 1 ϫ 10 4 cells/well and allowed to attach for 24 h before treatment. Neuronal cell death was promoted by exposure to MPP ϩ under 0.5% FCS for 48 h or by depriving cells of serum support for up to 72 h. Cell viability was evaluated by a colorimetric assay for mitochondrial function using the MTT test, as described previously (27) . The absorption was determined in a Tecan Sunrise Eliza-Reader (Switzerland) at ϭ 570/650 nm after automatic subtraction of background readings.
A cell death detection enzyme-linked immunosorbent assay kit (Roche Applied Science) was used to detect apoptosis. The assay is based on a quantitative sandwich enzyme-linked immunosorbent assay, with antibodies directed against DNA and histones to detect mono-and oligonucleosomes in the cytoplasm of cells undergoing apoptosis. The absorption was determined in a Tecan Sunrise ElizaReader (Hombrechtikon, Switzerland) at ϭ 405/490 nm after automatic subtraction of background readings.
Immunoblotting Analysis-Equivalent amount of proteins from SN4741 cells plated in 6-well culture dishes and treated as indicated were resolved by SDS-PAGE, and the protein levels were analyzed by means of Western blotting procedures (28) g) was denatured and reverse transcribed using random hexanucleotides (0.5 g/l) as previously described (29) . Q-PCR, was performed by LightCycler and FastStart DNA Master SYBR Green I ready-to-use PCR mix, according to the manufacturer's protocol (Roche Applied Science). cDNA was amplified in 20 l of total volume. The sequence-specific primers used for Q-PCR are depicted in Table 1 . The results were analyzed on the provided program of the LightCycler. The relative expression level of a given mRNA was assessed by normalizing to the housekeeping genes 18 S rRNA and/or ␤-actin compared with control values.
Immunocytochemistry and Confocal Microscopy-The cells were grown on polylysine-coated glass coverslips under permissive or differentiative conditions as described FIGURE 1. RNA interference-mediated silencing of SKP1A in SN4741 cell line. A, SN4741 cells were infected for 1 week with LVs plasmid vectors encoding shRNAs targeting SKP1A, shRNA-1, and shRNA-2 or a scrambled sequence. RNA was extracted and converted to single-stranded for analyzing by Q-PCR. The relative expression level was assessed by normalizing to the housekeeping genes 18S-rRNA and ␤-actin. The values are the means Ϯ S.E. from two independent experiments conducted in two to five replicates. *, p Ͻ 0.01 versus control (scrambled). B, after lentiviral infection cells homogenates were analyzed by Western blotting using Skp1 specific antibody. The bands were quantified by densitometry and normalized to ␤-actin. C and D, scrambled or shRNA-1 infected cells were grown with 10% FCS at 33°C, and after fixation and permeabilization, Skp1 protein was detected by fluorescence microscopy. The images are representative fields from two independent experiments. The chart represents the mean immunoreactive densities of six to nine separate fields from two independent experiments normalized to number of cells in each field. *, p Ͻ 0.01 versus control (scrambled).
TABLE 1 Sequences of primers for Q-PCR

Gene primer
Sequence
above up to 48 h and rinsed three times in cold phosphatebuffered saline (PBS), fixed, and permeabilized with Triton X-100 (0.1%) in sodium citrate (0.1%) for 5 min, as described (30) . The cells were blocked with PBS containing 10% donkey serum at 37°C for 1 h and incubated at 4°C overnight with mouse monoclonal antibody against Skp1 p19 (H-6, antibody sc-5281, 1:25; Santa Cruz, CA), rabbit polyclonal antibody against ubiquitin (antibody ab19247, 1:100; Abcam, Cambridge, MA), mouse monoclonal anti-Hsc-70 antibody (antibody SM5072, 1:25; Acris Antibodies, Herford, Germany), mouse monoclonal ␣-synuclein (␣-synuclein) antibody (antibody 610786, 1:25; BD Biosciences Transduction Laboratories, Heidelberg, Germany), rabbit polyclonal anti-tyrosine hydroxylase (TH) antibody (antibody AB152, 1:150; Millipore, Billerica, MA), mouse monoclonal anti-␥-tubulin antibody (antibody T6557, 1:10,000; Sigma), rabbit polyclonal antibody to 19 S regulator ATPase subunit Rpt3 (antibody PSMC4/S6b/ TBP7; PW8175, 1:150; Enzo Life Sciences, formerly Biomol, Plymouth, PA), all diluted in PBS containing 1% donkey serum and 0.05% Triton X-100. The wells were aspirated and rinsed twice with PBS for 10 min before the addition of secondary antibodies (see "Materials") at room temperature in the dark for 1 h. Immunofluorescence was observed using a 60ϫ objective (NA 1.4) and a Radiance 2000 confocal system (Bio-Rad) supported with Laser-Sharp 2000 software. Quantification of Skp1 was calculated with AnalySIS 4.0 imaging software (Soft Imaging System, Lakewood, CO), using an AX70 microscope system with a DP70 camera (Olympus, Melvile, NY). Flow Cytometry Analysis of Nuclear DNA Content-The cells were detached at different time points (up to 48 h) and centrifuged at 200 ϫ g for 5 min. The pellets were gently fixed with 70% EtOH, washed twice with PBS, and resuspended in a hypotonic fluorochrome solution (12.5 l of Triton X-100 (20%) and 5 l of DNase-free RNase (10 mg/ml) in 500 l of PBS). Subsequent to incubation for 30 min at 37°C, 10 l of 50 mg/ml propidium iodide was added to each sample and placed in the dark at room temperature for an additional 10 min. DNA content analyzed by FACSCalibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ) with Cell Quest research software; 3 ϫ 10 4 events/sample were acquired, and the percentage of cells in the G 0 /G1, S, and G 2 fractions was determined (31) .
Plasmid Construction and Transfection-The mammalian expression vector for SKP1A (pcDNA3.1 hygro -SKP1A) was constructed by inserting full size SKP1A cDNA between the BamHI and XbaI sites of pcDNA3.1 (Invitrogen). SN4741 cells in 10-cm 2 culture dishes in growth medium containing 10% FCS at a 70 -80% confluence were stably transfected with 10 g of the plasmids using GeneJammer transfection reagent (Stratagene, La Jolla, CA) for 24 -72 h. The medium was removed and replaced with supplemented antibiotics hygromycin (200 g/ml) for stable transfection. For negative control experiments, the pcDNA3.1 hygro empty vector was used. SN4741 stably transfected cells in 96-well plates were exposed to proteasome inhibitor MG-132 (12.5 and 25 M, dissolved in Me 2 SO) in 10% FCS for 6 h, and the medium was replaced with 2% FCS for an additional 10 h. Neuronal cell injury was evaluated by MTT test.
Animal Treatment and Protein Expression in Midbrain-All of the procedures were carried out in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals and were approved by the Animal Ethics Committee of the Technion (Haifa, Israel). Male C57/BL6 mice (20 -22 g; Harlan) were housed with a 12-h light interval. The mice were acclimatized for 5 days before any treatment. 6 -9 FIGURE 2. Effect of SKP1A silencing on cell cycle progression. A, lentivirus-infected SN4741 cells were seeded in Dulbecco's modified Eagle's medium with 10% FCS and puromycin for selection. SKP1A-infected cells appear less dense than their corresponding control (scrambled vector). Pictures were acquired after 24 h, using an inverted microscope connected to a digital camera (20ϫ objective). B, shRNA-1, shRNA-2, and scrambled vector infected cells were gently suspended in a hypotonic fluorochrome solution, incubated in the dark at 37°C for 30 min, and analyzed for DNA content on a logarithmic scale by FACSCalibur flow cytometer with Cell Quest research software; 3 ϫ 10 4 events/sample were acquired. Both shRNAs decreased the number of cells in G 0 /G 1 and increased the number of cells in S phase, with a delay in completion the cell cycle. The values are the means Ϯ S.E. from three independent experiments conducted in three replicates. *, p Ͻ 0.05; **, p Ͻ 0.01 versus control scrambled vector infected cells.
mice were assigned per each experimental group. MPTP was administrated for 4 days (20 mg/kg/day intraperitoneally), followed by a further 4-day resting period (8 days) to induce a progressive dopaminergic damage and to ascertain that all of the metabolite of MPTP, MPP ϩ , has been excreted from the body (32) . Midbrains were isolated and homogenized for Western blotting as described (33) . The proteins were identified using rabbit polyclonal anti-Skp1 antibody (#2156, 1:1000; Cell Signaling) and mouse monoclonal anti-TH antibody, (#T1299, 1:10000; Sigma). The optical density bands values from the autoradiograms were normalized to ␤-actin (see "Materials").
Statistical Analysis-The data are expressed as the means Ϯ S.E. and are compared between experimental groups with the use of one-way analysis of variance followed by Tukey's post hoc test unless otherwise specified (Analyze-it software for Windows Excel, Leeds, UK). Probability values of p Ͻ 0.05 or less were considered statistically significant. Differences in the animal experiments were evaluated by nonparametric KruskalWallis analysis of variance, followed by the Mann-Whitney two-tailed U test.
RESULTS
Small Interference RNA-mediated Down-regulation of SKP1A Gene and Protein in SN4741 Cells-Two different sequences of shRNA-encoding LVs targeting the transcript of murine SKP1A were assayed to endogenously generate small interference RNA-mediated silencing of SKP1A (designated shRNA-1 and shRNA-2). Q-PCR analysis revealed a significant decrease in mRNA of SKP1A (ϳ70 -80% reduction) compared with scramble shRNA-infected cells (Fig. 1A) . A similar downregulation of SKP1A mRNA by the two shRNA vectors was obtained when Q-PCR values were normalized to either ␤-actin or 18 S rRNA. Confirmatory Western (Fig. 1B) and immunofluorescence labeling (Fig. 1, C and D) of Skp1 protein showed ϳ75 and ϳ60% reductions in the expression levels of Skp1 protein in cells infected with both LVs or with shRNA-1, respectively.
SKP1A Silencing Induces Cell Morphology and Cell Cycle Alterations-SKP1A silenced cells display distinctive phenotypic characteristics when compared with the control. As shown in Fig. 2A , RNA interference-mediated SKP1A inhibition caused neurite extensions and thinner cell bodies, compared with shRNA-scrambled infected cells. Also, SKP1A-shRNA infected cells appear less dense than control, suggesting a defect in cell replication. This result prompted us to initially examine the effect of SKP1A gene silencing on cell cycle progression. FACS analysis revealed that infection with either shRNA-1 or shRNA-2 diminished the population of G 0 /G 1 phase cells from 44.0% (scrambled) to 37.0 and 39.3%, respectively, and increased the number of cells in S phase from 25.3% to 32.7 and 29.1%, with a delay in completion the cell cycle ( S1A ). SKP1A-shRNA infected cells that were exposed to 250 M MPP ϩ for a period of 48 h showed an increased vulnerability to the neurotoxin compared with nonsilenced cells (survival extent: 68.0 Ϯ 1.8, 53.9 Ϯ 1.1, and 45.0 Ϯ 1.3%, for scrambled SKP1A shRNA-1 and shRNA-2, respectively) (supplemental Fig. S1B ), as determined by MTT reduction test. Similar results were obtained when assessing the index of apoptosis by cell death enzyme-linked immunosorbent assay kit (supplemental Fig. S1C ). The findings reveal for the first time a vital role for Skp1 in dopaminergic cell function and survival.
RNA Interference-mediated SKP1A Inhibition Reduces the Expression of Dopaminergic Markers in SKP1A-silenced Cells-
To further examine the role of Skp1 in dopaminergic neuron phenotype, we assessed the gene expression of phenotypic markers of DA neurons in Skp1-deficient cells. Given the similar results obtained with the two SKP1A shRNA LVs, shRNA-1 was selected for further studies. Q-PCR analysis showed that SKP1A shRNA-1-mediated silencing caused a significant decline in DAT and VMAT2 mRNA (ϳ43 and ϳ27% of scrambled vector, respectively), both being key components in the regulation of DA disposition in the synapse and cytosol. Another gene whose expression was significantly down-regulated (ϳ44%) was ALDH1A1 (Fig. 3) . This isoform was found to be expressed highly and specifically in DA cells of the SN and ventral tegmental area (36) Fig. 4A , the protein expression level of Skp1 was increased up to 6.3-fold over the control level (cells transfected with pcDNA3.1 hygro -empty vector). The overexpression of Skp1 protein was found to protect the dopaminergic cells against damage induced by exposure to MPP ϩ (150 and 250 M) for 48 h (Fig. 4B ) (survival was increased from 61.1 Ϯ 1.4 to 77.5 Ϯ 1.5% at 150 M and from 44.3 Ϯ 1.8 to 57.1 Ϯ 1.3% at 250 M). A more robust protection was afforded in cells injured by pharmacological inhibition of the proteasome. Fig. 4C shows that neuronal cultures transfected with Skp1 duplicated the survival index of naïve SN4741 exposed for 6 h to the reversible proteasome inhibitor, peptide aldehyde MG-132 (12.5 and 25 M) (from 39.6 Ϯ 0.7 to 52.9 Ϯ 0.6% and from 23.9 Ϯ 0.8 to 43.9 Ϯ 0.4%, respective to each concentration) compared with empty vector-transfected cells. Thus, Skp1 overexpression can protect DA neurons from proteasome inhibition-and toxin-mediated cell damage.
Skp1 Deficiency Is Lethal to Differentiated SN4741-Because adult neurons in the brain are in a state of terminal differentiation, we sought to examine whether the silencing of the SKP1A gene would have any phenotypic effect in cells exiting the cell cycle. SN4741 cells carried the temperature-sensitive mutant from the oncogene, SV40Tag-tsA58 and proliferated at 33°C with a doubling time of 36 h, having a fibroblast-like flat morphology with less prominent neurite growth (Fig. 5A) . However, when naïve SN4741 cells are shifted to the nonpermissive temperature of 39°C and FCS is reduced to 0.5%, they cease to proliferate and after 48 h display a neuronal morphology with extensive neurite outgrowth and long bipolar or multipolar processes (Fig. 5A, arrows) (37) . Indeed, FACS analysis showed an increased number of cells in G 0 /G 1 (60.17 Ϯ 2.66% at the restrictive temperature, compared with 44.0 Ϯ 0.9% at the permissive temperature), whereas the number of proliferating cells in the S phase and G 2 /M phase dropped considerably from 25.3 Ϯ 0.6 to 2.9 Ϯ 0.3% and from 25.5 Ϯ 0.8 to 7.1 Ϯ 0.4%, respectively (Fig. 5B) . The indication of a differentiation state was further corroborated by monitoring the gene expression of the DA neuron-specific markers, DAT, TH, VMAT2, and ALDH1A1, which, as expected, were significantly up-regulated at the restrictive differentiation temperature (Fig. 5C, To test this hypothesis, SN4741 cells deficient in SKP1A were shifted to the restrictive temperature to induce differentiation and assayed by FACS for a period of 48 h. A prominent cell mortality was evident, as manifested by the appearance of cells with retracted short neurites and shrunken cell bodies, being accentuated with the duration of culture, compared with scramble-infected cells (Fig. 6A ). This was accompanied by a progressive reduction in the percentage of cells in G 0 /G 1 (Fig.  6B ) in parallel to an increase in the S phase, indicating an attempt to escape from cell cycle arrest. To rule out any possible contribution of conformational changes in proteins that might have occurred when shifting the cells to 39°C, differentiation was also induced by adding the well established regulator of cell growth and differentiation, retinoic acid (10 M). A similar picture was obtained after daily exposure to retinoic acid (Fig. 6C) .
SKP1A Deficiency Caused Proteinaceous Inclusion Formation in Differentiated SN4741
Cells-Excessive accumulation of misfolded proteins and inhibition of proteasomal function are considered to promote formation of aggresome/LB-like inclusions and toxicity in cultured dopaminergic neurons (15, 16) . Because Skp1 is a member of SCF complex that functions as an E3 ubiquitin ligase, we conjectured that silencing of SKP1A by mRNA interference might cause protein accumulation and possible formation of proteinaceous inclusions. SN4741 neurons infected with SKP1A shRNA-1 and grown at a permissive temperature did not show any cytoplasmic aggregates, similar to cells infected with the scrambled vector (Fig. 7, A and C) . However, SKP1A-deficient cells under differentiation process develop cytosolic round inclusion structures that stain positively for ␣-synuclein, TH, ubiquitin, proteasomal ATPase subunit PSMC4, and Hsc-70 (Fig. 7, B, D , and E, arrows, and supplemental Fig. S2 ), all of which are components of LBs (38 -40) . Some of them appeared as a single perinuclear inclusion aggregate (insets), reminiscent of centriole-associated structures termed aggresomes (41, 42) , characterized by the presence of intermediate filaments such as ␥-tubulin (Fig. 7F) , which colocalized with ubiquitin and the proteasome subunit, PSMC4 (Fig. 7, F and G (1, 6) and in long term MPP ϩ -treated SN4741 neurons. To further elucidate the involvement of Skp1 in dopaminergic neurodegeneration, we first conducted a time course study with naïve SN4741 dopaminergic cells exposed to MPP ϩ (250 M) for various time intervals, and the expression of Skp1 was monitored by Western blotting (supplemental Fig. S3A ). MPP ϩ caused an acute (2 h) down-regulation of Skp1 protein (54.0 Ϯ 7.6 of control), returning to control values 12 h later and a long term (48 h), more pronounced reduction (to 28.0 Ϯ 7.6% of control) (supplemental Fig. S3B) . Similarly, the expression pattern of the dopaminergic marker ALDH1 and the chaperone Hsc-70, a member of the Hsp70 family followed that of Skp1 (at 48 h, 46.3 Ϯ 10.5 and 56.7 Ϯ 7.0% of control, respectively).
We next sought to extend these studies to the animal model of PD, employing the neurotoxin MPTP, the parental generator of MPP ϩ and measuring the levels of Skp1 in the midbrain, which contains the DA-producing neurons of the SNpc. The protein level of Skp1 was significantly decreased (37.3 Ϯ 8.1%) in the midbrain of MPTP-injured mice compared with vehicletreated mice, further supporting the assumption of a crucial role of Skp1 in dopaminergic function (Fig. 8, A and B) . A parallel decline was seen in TH protein content. To assess the relative abundance of Skp1 in the brain, protein lysates from dif- A, SKP1A silenced (shRNA-1 infected) and nonsilenced cells (scrambled) seeded in 10% FCS-containing medium were induced to differentiate for up to 48 h. There is a robust lethality in cultures of cells deficient in SKP1A that were induced to differentiate at restrictive temperature, compared with the viability and differentiative phenotype of scrambled vector-infected cells. The pictures were acquired using an inverted microscope connected to a digital camera (10ϫ objective). B, cells were analyzed for DNA content by FACS. The percentage of cells in the G 0 /G 1 , S, and G 2 /M fractions was calculated. The values are the means Ϯ S.E. from three independent experiments conducted in three replicates. *, p Ͻ 0.01 versus scrambled. C, differentiation with retinoic acid (10 M). ferent brain areas of naïve mice were electrophoresed and blotted with an antibody against Skp1. Fig. 8C reveals that the midbrain and striatum contain the lowest Skp1 protein levels, compared with frontal cortex, hippocampus, and cerebellum (data not shown for the latter).
DISCUSSION
The results of the present study show that Skp1 deficiency leads to a lethal phenotype in arrested/post-mitotic SN-derived cells, suggesting that Skp1 may play a crucial role at the interface between the cell cycle, differentiation, and death. This observation links, for the first time, Skp1 to DA neuronal function and survival, suggesting an essential role in sporadic PD. Support for a central role of Skp1 in dopaminergic neuron phenotype is provided by the prominent elevation in both SKP1 gene and protein levels upon cell cycle arrest-induced differentiation, in parallel to the DA neuron markers DAT, TH, VMAT2, and ALDH1A1. As far as we know, this is the first report of Skp1 as a potential player in neuronal maturation.
There are at least two possible explanations for the lethal phenotype demonstrated in SKP1A silenced, arrested cells. The reduced expression of Skp1 protein may cause the malfunction of the E3 ligase SCF complex and subsequent dysregulation of cell cycle regulators of the G 1 /S transition, such as cyclins, cyclin-dependent kinases, and cell cycle inhibitors (7, 43) . It is well known that in neurodegenerative diseases there is a loss of cell cycle control, leading eventually to neuronal death (44) . Indeed, events that force mature neurons back into the cell cycle are lethal rather than mitogenic for the neuron. In line with this, knockdown of two components of the ubiquitin pro- teasome system, the ubiquitin ligase scaffolding protein Cul-1 and the proteasome-associated deubiquitinating protein Pad-1, lead to cell cycle reactivation and apoptosis in subsets of postmitotic neurons (45) . Alternatively, but not mutually exclusive, Skp1 might have a structural or functional role in the cell, essential to cell survival and differentiation processes in higher organisms. A first functional link between Skp1 and tissue cell degeneration in mammals has been provided only lately in mice null for Fbx2, a brain enriched F-box protein that appears to function with Skp1 in an apparently novel heterodimeric complex, rather than in the traditional SCF tetramer in inner ear cochlear tissue. Here, the deficiency of Fbx2 led to a parallel loss of Skp1 specifically in the cochleae and cellular degeneration, resulting in age-related hearing loss (46) . There was no indication, however, regarding the expression levels of Skp1 in the SN of these Fbx2 null mice and whether the integrity/function of the DA neurons was compromised. Consistent with these finding is that in yeasts Skp1 was found to associate with the F-box protein RCY1 without assembling into an SCF complex and to participate in the recycling of internalized proteins (47) . Parkin has been found to function in a SCF-like multiprotein complex that includes the F-box/WD repeat protein hSel-10 and Cullin-1, and cyclin E was identified as a target of this complex (48) . This composite activity of parkin may potentially increase the repertoire of proteins targeted for ubiquitination.
The finding that SKP1A is decreased in SNpc from PD patients suggests a broad impairment in the function of an entire selection of proteins, leading to their inappropriate expression or activation and eventually cell death. Indeed, our and other's laboratories microarray transcriptomic studies of sporadic PD SNpc (1-5) have identified, together with SKP1A, down-regulation of genes expressing dopaminergic phenotype (i.e. DAT, aromatic amino acid decarboxylase (AADC), AMP-regulated phosphoprotein (ARPP-21), ALDH1A1, and VMAT2) and vesicle trafficking and synaptic transmission (i.e. synaptotagmin 1 (SYT1), syntaxin-1A (STX1A), synaptogyrin 3 (SYNGR3), and N-ethyl maleimide-sensitive factor). Under normal physiological conditions, DAT and VMAT are key components in the regulation of DA disposition in the synapse and cytosol. Following vesicular DA release into the synapse, the DAT transports DA from the presynaptic area into the cytosol of the presynaptic nerve terminal of DA neurons (49) . Given that ALDH1, VMAT, and DAT are located within DA-containing neurons of SNpc, the reduction in their gene expression may contribute to a failure in DA transmission and metabolism. In agreement with the human findings, the shRNA-mediated decrease of Skp1 induced a parallel down-regulation of DAT, VMAT2, and ALDH1A1 mRNA. In addition, Skp1-deficient cells displayed decreased expression levels of HSPA8, coding for the HSP70 family chaperone Hsc-70, which is responsible for recognizing unfolded or aberrant proteins. Its gene and protein levels were found significantly reduced in sporadic PD (1, 6) . This may exacerbate the accumulation of a wide spectrum of ubiquitinated protein aggregates in PD brains such as TH, synphilin-1, ␣-synuclein, and phosphorylated tau (19, 50) . Indeed, we found proteinaceous round inclusion structures that stained positively for ␣-synuclein, TH, ubiquitin, 19 S proteasomal protein PSMC4, and Hsc-70, all components of LBs. Some inclusions presented as single perinuclear ␥-tubulin-positive aggregates, reminiscent of centriole-associated structures termed aggresomes (51) . It is tempting to speculate that a similar process may occur in the dopaminergic neurons of PD patients, where these structures may represent a precursor of LBs. As far as we know this is the first report showing that a deficiency in an E3 ubiquitin ligase, identified as significantly reduced in human SNpc from sporadic PD, promotes the formation of aggresome-like inclusions and ultimate cell death, occurring only in differentiated neurons. Thus, the present finding can suggest a novel paradigm in which dysfunction of Skp1 promotes LB-like inclusion body formation rather than the presence of these inclusions as the culprit of DA neuron death. Interestingly, in parkin-related PD there is a general absence of LB inclusions in post-mortem brain samples of patients, and sporadic PD brains do not present alterations in the mRNA or protein levels of parkin.
In support for a protective role of Skp1 in brain function, we found a significant decrease of Skp1 in MPTP-parkinsonian mice, specifically in the midbrain in correlation with a loss of TH protein. Furthermore, our results demonstrated that the midbrain and striatum contain the lowest Skp1 protein levels, compared with frontal cortex, hippocampus, and cerebellum, probably contributing to the particular susceptibility of the SNpc dopaminergic neurons to different types of stresses such as increased iron concentration, enzymatic (monoamine oxidase) and nonenzymatic (auto-oxidation) DA metabolism, abnormal protein accumulation, proteasomal inhibition, and neurotoxin-induced OS. In agreement with our findings in humans and MPTP-induced parkinsonism, cultured naïve SN4741 DA neurons exposed to the DA neuron-selective neurotoxin MPP ϩ , a dynamic producer of ROS, caused an early and progressive down-regulation of Skp1, concomitantly with ALDH1 and Hsc-70 proteins. This finding further supports the view of these proteins as intimately connected to the neuronal death process in sporadic PD and probably, acting as early players in the neurotoxic cascade. It has been proposed that subtle alterations in a small number of interconnecting crucial genes, occurring during the presymptomatic manifestation of PD, account for the slowly progressive neurodegeneration of the DA-containing neurons (52) . It is possible that the gradual functional decrease in Skp1 and its dopaminergic counterparts shown in this study represents a "convergence point" shared by both the familial and sporadic cases. Further comparative studies in familial versus sporadic PD brains would shed light on the similarities between both forms of the disease and the role of Skp1. Future studies aimed at silencing the corresponding genes might reveal novel molecular counterparts and their interplay in PD.
Although Skp1-deficient neurons begin to die in the process of differentiation, morphological and biochemical changes were already apparent in proliferating cells. The cells acquired an elongated and thinner cell body and divide more slowly because of a delay in completion of the cell cycle. In addition, significant reductions in the expression of some DA markers were also evident. These changes are presumably involved in the increased sensitization of Skp1 knockdown cells to damage induced by MPP ϩ and serum withdrawal, further supporting a defensive role of Skp1 in dopaminergic neurons. By contrast, overexpression of Skp1 protein conferred protection to naïve SN4741 dopaminergic cells against damage induced by exposure to MPP ϩ and pharmacological inhibition of the proteasome. The observation that Skp1 is still able to rescue SN4741 cells under proteasomal inhibition implies a distinct function of Skp1, unrelated to its E3 ubiquitin ligase activity. This assumption merits further investigation. Indeed, we are currently performing immunoprecipitation studies to elucidate the putative interacting partners of Skp1 in neuronal cultures and mice midbrain tissue.
In summary, the data presented here suggest that Skp1 plays a fundamental role in DA neuron viability in the context of cell cycle arrest and differentiation. Indeed, its deficiency has reproduced to a significant extent the molecular alterations described in sporadic PD at the cellular level. This and the protection afforded by Skp1 overexpression support its genetic manipulation as a new model of sporadic PD. The understanding of the functional/structural role of Skp1 and its mechanism of action may lead to novel therapeutic approaches targeted at its molecular pathway counterparts.
